{"name":"Matinas BioPharma","slug":"matinas","ticker":"MTNB","exchange":"NYSE American","domain":"mfrmpharma.com","description":"Matinas BioPharma is a biopharmaceutical company focused on developing innovative anti-infective therapeutics and drug delivery technologies. The company's pipeline includes several promising candidates, including MAT2203, a broad-spectrum antifungal agent. Matinas BioPharma has a strong presence in the anti-infectives market, with a focus on addressing the growing need for effective treatments against antibiotic-resistant infections.","hq":"Bedminster, NJ","founded":0,"employees":"","ceo":"Jérôme Jabbour","sector":"Anti-Infectives / Drug Delivery","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$60M","metrics":{"revenue":119750,"revenueGrowth":-20,"grossMargin":0,"rdSpend":11433000,"netIncome":-24251000,"cash":12641000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"MAT2203 patent cliff ($0.0B at risk)","drug":"MAT2203","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MAT2203","genericName":"MAT2203","slug":"mat2203","indication":"Invasive fungal infections (including aspergillosis and candidiasis)","status":"phase_3"}]}],"pipeline":[{"name":"MAT2203","genericName":"MAT2203","slug":"mat2203","phase":"phase_3","mechanism":"MAT2203 is a lipid nanoparticle formulation of amphotericin B designed to improve drug delivery and reduce toxicity in fungal infections.","indications":["Invasive fungal infections (including aspergillosis and candidiasis)","Cryptococcal meningitis"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Matinas BioPharma Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Matinas BioPharma reported its financial results for the fourth quarter and full year 2023, highlighting progress in its pipeline and commercial operations.","drugName":"","sentiment":"neutral"},{"date":"2023-11-16","type":"deal","headline":"Matinas BioPharma Announces Collaboration with University of California, San Diego to Develop Novel Antifungal Therapies","summary":"Matinas BioPharma entered into a collaboration with the University of California, San Diego to develop novel antifungal therapies using its lipid nanocrystal (LNC) technology.","drugName":"","sentiment":"positive"},{"date":"2023-08-14","type":"trial","headline":"Matinas BioPharma Announces Positive Topline Results from Phase 2 Clinical Trial of MAT2203 in Invasive Aspergillosis","summary":"Matinas BioPharma announced positive topline results from a Phase 2 clinical trial of MAT2203 in invasive aspergillosis, demonstrating its potential as a broad-spectrum antifungal agent.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNX3pXc1A4ZlhQT3I5Mkc4aWxaV0J3dmI1S25JcUlhVEkyVUpfSjY1UjJUcW9nLTE5eTB0QndKTWdrZmFPdDJGVm1yQnRUc2pNSklFdV9WakxrT0ZQREM1MFpXWXRPbjB2UXIwbWNZSTlVa0RnN3JfdHBzU1gzVzlGSDBCWFdYNU0?oc=5","date":"2026-04-04","type":"pipeline","source":"Intellectia AI","summary":"Matinas BioPharma Faces NYSE Compliance Issues - Intellectia AI","headline":"Matinas BioPharma Faces NYSE Compliance Issues","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOZGNicEtaZlJxeEtrZG05eUpTZXI2QmprS0htaWZWME9FcmhvZnR0VEJsSDNwa0VmeGhONjlOZ2hoaGxlcHBPaWNSZDBIbkREYzZibGFReHlPOTA2Nmw0M3NuUGd5aFVVUndwemhveWxoZTNUMHduY25aYXIwSTVjUWZMTVlNNFo1WVAxZzRsMTN6RjhqeHF6c0VRbkt5TFFZejJoNGRPTjhfSjkwX3RfNzlyd05uVEFE?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Matinas BioPharma has until May 2 to answer NYSE notice - Stock Titan","headline":"Matinas BioPharma has until May 2 to answer NYSE notice","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOY0dzVkprdlhEQnplRVFxTVJfZk9fTl9oOVcybjd3NWJXcWVJM1Frc3JvSGhLOTFyMUtOaHJZV0lNSTlmYmdDazNlOFJxcWppaVZCOHQ0MmF2MDdvekFFdkNNTEYxM3M0NzdCVW10dWEtSkRiYUlFZHBjVHRJOEgwNWZLNHFxalF2VnNia241b01odHYwaGEySnQ0aUlwdlJfdmhnZWRCRERzY3pMM3R3cGkzb1JraFUxT3RqSA?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Matinas BioPharma (NYSE American: MTNB) faces NYSE non-compliance and cure deadline - Stock Titan","headline":"Matinas BioPharma (NYSE American: MTNB) faces NYSE non-compliance and cure deadline","sentiment":"neutral"},{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOR1hxdTlDMHhuQkd2TzhYaEhkZk8tdFhhT19UVjJmWmxCWV85RElmR1RXUW9ZTEJ1TzQ5YXVjMFRDaXk0M2h6RzNKeV9ZTElxek5WYjFNRWEtTEdJUkVzQmpMRFVRamd3SHVRTnhVTWhuWUtHdElja2g0Mk5tSFJkMFktM3lVcVQ2OFZYVlg3NWwxSWRJMXdaMVFKakkyVjdIal9BSEpIUnZlSFFUeF9mMzBZZFRqRGts?oc=5","date":"2026-03-04","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Wednesday's Pre-Market Session - 20/20 Biolabs (NASDAQ:AIDX), Can Fite Bi - Benzinga","headline":"12 Health Care Stocks Moving In Wednesday's Pre-Market Session - 20/20 Biolabs (NASDAQ:AIDX), Can Fite Bi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQT2w1LXhrbHZBYll6WVRBVFE5bHdwNG1UbnBFZWtmT2RtRG5NM20wTUlSRXBXNVNWRVlObEh5bzR5YmU2d2lfaXNDc05RZ0RldVYzOUFpYW5ZcGY5RVJlMV9lY3ZCY1daaEdfcFIwc3dvSjRQWmtybEh5d2NWSUlWYXZUSVRUdjhRcldaSVdKZ0JUZHY5WmY5ZkdZUG00QnBUVTJPalc5Zkh6OGRLT0ZLZ2k1emR5cXR0MzEySDVNMHJ0X1o4SVI2NVFZSlplY3RSMWpaUjRmUEM?oc=5","date":"2026-01-24","type":"pipeline","source":"The Globe and Mail","summary":"Matinas BioPharma CEO Named Interim Chief Financial Officer - The Globe and Mail","headline":"Matinas BioPharma CEO Named Interim Chief Financial Officer","sentiment":"neutral"},{"date":"2026-01-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-10","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-08-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-08-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-08-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-06-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[{"drugName":"MAT2203","drugSlug":"amphotericin-b","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Merck & Co.","Pfizer Inc."],"therapeuticFocus":["Anti-infectives","Drug delivery"],"financials":{"source":"sec_edgar+yahoo","revenue":119750,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":119750,"period":"2018-12-31"},{"value":149687,"period":"2017-12-31"},{"value":149687,"period":"2017-12-31"},{"value":0,"period":"2016-12-31"},{"value":194494,"period":"2015-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":11433000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-24251000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":12641000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}